UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 30, 2013
NxSTAGE MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-51567 | | 04-3454702 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | | | | | |
| 350 Merrimack Street, Lawrence, MA | | 01843 |
| (Address of principal executive offices) | | (Zip Code) |
(978) 687-4700
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01. | Entry into a Material Definitive Agreement. |
Extension of Terms of Supply and Distribution Agreement with Kawasumi Laboratories, Inc.
On January 30, 2013, Medisystems Corporation (“Medisystems”), a wholly-owned subsidiary of NxStage Medical, Inc. (“NxStage”), and Kawasumi Laboratories, Inc. (“Kawasumi”) agreed to extend the terms of their Supply and Distribution Agreement dated as of February 1, 2001. The Agreement, which governs Medisystems’ purchase of needle sets from Kawasumi, will now be extended to February 1, 2017, which term may be extended by the mutual agreement of the parties.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | NxStage Medical, Inc. |
| | | |
| Date: January 31, 2013 | | | | By: | | /s/ Jeffrey H. Burbank |
| | | | | | | | Jeffrey H. Burbank President and Chief Executive Officer |
